Jamie Wood

Jamie Wood
National Institute for Biological Standards and Control · Advanced Therapies

Master of Science

About

7
Publications
156
Reads
How we measure 'reads'
A 'read' is counted each time someone views a publication summary (such as the title, abstract, and list of authors), clicks on a figure, or views or downloads the full-text. Learn more
1
Citation
Citations since 2016
7 Research Items
1 Citation
20162017201820192020202120220.00.51.01.52.02.53.0
20162017201820192020202120220.00.51.01.52.02.53.0
20162017201820192020202120220.00.51.01.52.02.53.0
20162017201820192020202120220.00.51.01.52.02.53.0

Publications

Publications (7)
Article
Full-text available
Genetic evidence indicates disrupted epigenetic regulation as a major risk factor for psychiatric disorders, but the molecular mechanisms that drive this association remain to be determined. EHMT1 is an epigenetic repressor that is causal for Kleefstra Syndrome (KS), a genetic disorder linked with neurodevelopmental disorders and associated with sc...
Preprint
Full-text available
Genetic evidence indicates disrupted epigenetic regulation as a major risk factor for psychiatric disorders, but the molecular mechanisms that drive this association are undetermined. EHMT1 is an epigenetic repressor that is causal for Kleefstra Syndrome (KS), a neurodevelopmental disorder (NDD) leading to ID, and is associated with schizophrenia....
Article
BACKGROUND: Pre-clinical tumour models lack human stromal cells and are inadequate for the assessment of novel tumour microenvironment targeted therapies. An increase in combination opportunities requires a higher throughput in vitro assay that utilised the patient relevant model. The 3D-tumour growth assay (3D-TGA) enables patient-derived tumour c...
Conference Paper
Background: Hepatocellular carcinoma (HCC) is an aggressive disease with limited therapeutic treatment options. Checkpoint inhibitors are widely being evaluated in numerous cancers including HCC, but suitable preclinical models are required. Subcutaneous syngeneic models are widely used to evaluate the impact of immunotherapy on tumor growth and tu...
Conference Paper
Background: Preclinical in vitro and in vivo tumor models lack human stromal cells and are inadequate for the assessment of novel tumor microenvironment-targeted therapies. Here we report on a 3D-tumor growth assay (3D-TGA) in which patient-derived tumor cells are admixed with a basement membrane extract and bone marrow-derived mesenchymal stem cel...
Article
BACKGROUND: Glioblastoma Multiforme (GBM) is the most common and malignant primary tumour of the Central Nervous System (CNS), with no effective current treatment options available. Median overall survival after radical surgical resection with intensive adjuvant radiotherapy and temozolomide is just 15 months. As a result, there remains a critical...
Conference Paper
BACKGROUND: Glioblastoma Multiforme (GBM) is the most common and malignant primary tumour of the Central Nervous System (CNS), with no effective current treatment options available. Median overall survival after radical surgical resection with intensive adjuvant radiotherapy and temozolomide is just 15 months. As a result, there remains a critical...

Network

Cited By